Hepatocellular carcinoma: is current therapy really altering outcome?

Progress in the management of hepatocellular carcinoma (HCC) has been slow and has limited impact on outcome. Most patients with HCC have two diseases—chronic liver disease and HCC—and complex interactions between the two have major implications for diagnosis and prognosis as well as the management...

Full description

Saved in:
Bibliographic Details
Published in:Gut 2002-10, Vol.51 (4), p.459-462
Main Author: Johnson, P J
Format: Article
Language:English
Subjects:
AFP
Analysis
Biological and medical sciences
Cancer patients
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - surgery
Carcinoma, Hepatocellular - therapy
Care and treatment
Chemotherapy
Clinical trials
Complications and side effects
Diagnosis
Drug Resistance, Neoplasm
HCC
Health aspects
hepatocellular carcinoma
Hepatoma
Humans
Iodized Oil - therapeutic use
Leading
Liver cancer
Liver cirrhosis
liver disease
Liver diseases
Liver Neoplasms - drug therapy
Liver Neoplasms - surgery
Liver Neoplasms - therapy
Liver Transplantation - methods
Liver, biliary tract, pancreas, portal circulation, spleen
Medical examination
Medical prognosis
Medical research
Medical sciences
Medicine, Experimental
Mortality
Multivariate analysis
Postoperative period
Prognosis
Radiotherapy
randomised clinical trial
RCT
Surgery
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Surgery of the digestive system
TOCE
transcatheter oily chemoembolisation
Treatment Outcome
Tumors
α fetoprotein
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Progress in the management of hepatocellular carcinoma (HCC) has been slow and has limited impact on outcome. Most patients with HCC have two diseases—chronic liver disease and HCC—and complex interactions between the two have major implications for diagnosis and prognosis as well as the management of HCC. The disease is most prevalent in those areas of the world where the infrastructure for clinical trials is least developed. Also, the aetiology of the disease varies around the world and it is still not known whether HCCs of different aetiologies have different prognoses. Current treatment is making an impact on the management of HCC but further progress awaits not only the development of more effective treatments but also the development of adequate methodologies to assess the impact of these treatments.
ISSN:0017-5749
1468-3288
1458-3288
DOI:10.1136/gut.51.4.459